Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement

Cancer

Volumn 101, Issue 8, 2004, Pages 1803-1808

  Frank, Igor ^a   Cheville, John C ^a   Blute, Michael L ^a   Lohse, Christine M ^a   Karnes, R Jeffrey ^a   Weaver, Amy L ^a   Sebo, Thomas J ^a   Nehra, Ajay ^a   Zincke, Horst ^a  

^a MAYO CLINIC   (United States)

Author keywords

Lymph node; Transitional cell carcinoma (TCC); Tumor marker; Urinary bladder

Indexed keywords

ANTINEOPLASTIC AGENT; KI 67 ANTIGEN; PROTEIN P53;

ARTICLE; BLADDER CARCINOMA; CANCER RECURRENCE; CYSTECTOMY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYSTECTOMY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 4744363663     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20567     Document Type: Article

References (26)

1. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050-1055.
2. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-2569.
3. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol. 1994;152:388.
4. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259-1264.
5. Lowe SW, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-967.
6. Sjogren S, Inganas M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996;88:173-182.
7. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. P53 and treatment of bladder cancer. Nature. 1997;385:123-125.
8. Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol. 2000;163:758-760.
9. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer. 2000; 88:2598-2605.
10. Suwa Y, Takano Y, Iki M, Asakura T, Noguchi S, Masuda M. Prognostic significance of Ki-67 expression in transitional cell bladder carcinoma after radical cystectomy. Pathol Res Pract. 1997;193:551-556.
11. Asakura T, Takano Y, Iki M, et al. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol. 1997;158:385-388.
12. Jones HL, Delahunt B, Bethwaite PB, Thornton A. Polyclonal Ki-67 expression in transitional cell carcinoma of the bladder. Pathology. 1997;29:84-87.
13. Frank I, Cheville JC, Blute ML, et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinic pathologic features associated with outcome. Cancer. 2003;97:2425-2431.
14. Kuczyk MA, Bokemeyer C, Serth J, et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer. 1995;31A:2243-247.
15. Gontero P, Casetta G, Zitella A, et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol. 2000; 38:287-296.
16. Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol. 1999;36:393-400.
17. Popov Z, Hoznek A, Colombel M, et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer. 1997;80:1472-1481.
18. Fleshner N, Kapusta L, Ezer D, et al. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive TCC of the bladder. J Urol. 2000;164:1177.
19. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol. 1998;29:146-154.
20. Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer. 1998;82:715-723.
21. Liukkonen TJ, Lipponen PK, Helle M, Jauhiainen KE. Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Finnbladder III Group. Urol Res. 1997;25:1-7.
22. Lianes P, Charytonowicz E, Cordon-Cardo C, et al. Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network. Clin Cancer Res. 1998;4:1267-1271.
23. Lara PC, Rey A, Santana C, et al. The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. Radiother Oncol. 1998;49:163-167.
24. Kakehi Y, Ozdemir E, Habuchi T, et al. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer Res. 1998;89:214-220.
25. Sengelov L, Horn T, Steven K. P53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J Cancer Res Clin Oncol. 1997;123:565-570.
26. Herr HW, Bajorin DF, Scher HI, Cordon-Cardo C, Reuter VE. Can p53 help select patients with invasive bladder cancer for bladder preservation [see comments]? J Urol. 1999;161:20-22; discussion 22-23.